ArticleCardiovascular diabetology. Endocrinology reports2026
Association of acylcarnitine species and diabetes incidence in a population-based apparently healthy cohort.
Article in Cardiovascular diabetology. Endocrinology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCurrent diabetes risk scores often fail to detect early metabolic changes. Acylcarnitines species (ACs), intermediates of mitochondrial fatty acid oxidation, may indicate early dysregulation in diabetes, but prospective evidence is limited. We investigated the associations between circulating ACs and 10-year incidence of diabetes, and whether AC improve the predictive performance of established diabetes risk scores.
methodsData from 1,976 apparently healthy adults in a population-based cohort. Incident diabetes was defined as HbA1c ≥ 48 mmol/mol or initiation of glucose-lowering medication at follow-up. Associations were analysed using bivariate and multivariate models, and predictive value was assessed by adding ACs individually to FINDRISC, SDA, Kahn clinic, Kahn clinic+biologic, Wilson, Balkau and Griffin scores.
resultsOver 10 years, 35 participants developed diabetes. Higher baseline levels of Propionyl-, Isovaleryl-, Hexanoyl-, and Octenoylcarnitine were associated with incident diabetes in bivariate analysis whereas only Propionylcarnitine remained associated in multivariate analyses, mean ± sem 376.3 ± 2.7 vs. 419.1 ± 20.4 nmol/L in non-Diabetes and incident diabetes, respectively, p < 0.05. Sensitivity analyses using both diabetes and prediabetes incidence showed similar pattern of associations compared to the primary analysis. In predictive analyses, Propionyl- and Isovalerylcarnitine remained independently associated with incident diabetes after adjustment for each established diabetes risk scores. Adding Isovalerylcarnitine to the risk scores improved discrimination in three out of seven risk scores: AUC 0.785 (0.710–0.859), 0.841 (0.789–0.892), and 0.841 (0.789–0.892) for Balkau, SDA and FINRISK, respectively.
conclusionSpecific AC species, particularly Propionyl- and Isovalerylcarnitine, predicted 10-year risk of diabetes and improved predictive performance beyond established risk scores, suggesting their potential as early metabolic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.